Blue Cross Laboratories Ltd. v. RB Remedies Pvt. Ltd. & Anr.

In the fiercely competitive pharmaceutical industry, brand names are more than just labels — they are lifelines of trust between companies, doctors, and patients. When two drug brands sound almost identical, the risk of confusion is not just a marketing problem; it is a public health concern. This case between Blue Cross Laboratories and RB Remedies Private Limited is a textbook example of how courts protect established brands from look-alike competitors, even at the interim stage before a full trial.

Blue Cross Laboratories, an established pharmaceutical company, owned and used the trademark 'CEDON' for its medicinal product. RB Remedies Private Limited entered the market with a product marketed under the mark 'CEFDON'. Blue Cross Laboratories believed that the two marks were deceptively similar, both visually and phonetically, and that consumers could easily confuse one for the other. Concerned about potential damage to its brand reputation and market share, Blue Cross Laboratories approached the Bombay High Court seeking an interim injunction to stop RB Remedies from using the 'CEFDON' mark. RB Remedies, on its part, attempted to get the plaint itself rejected, arguing that the suit should not proceed in its current form.

Blue Cross Laboratories argued that 'CEDON' and 'CEFDON' were deceptively similar, and that the addition of just two letters 'EF' was not enough to distinguish the two marks in the minds of consumers. The company built a prima facie case for both trademark infringement and passing off, contending that the similarity would mislead doctors, chemists, and patients into believing the products were related or affiliated. RB Remedies countered by attempting to have the plaint rejected on procedural grounds, suggesting that the causes of action should not be combined. The defendant also appeared to rely on the argument that its adoption of the mark was based on the principal drug name, implying honest and independent use.

The Bombay High Court ruled decisively in favor of Blue Cross Laboratories. The court found that the marks 'CEDON' and 'CEFDON' were indeed deceptively similar, both phonetically and visually, and that this similarity was sufficient to establish a prima facie case for trademark infringement and passing off. An interim injunction was granted, restraining RB Remedies from using the 'CEFDON' mark during the pendency of the suit. Importantly, the court also rejected RB Remedies' attempt to have the plaint thrown out, holding that combining the causes of action of infringement and passing off into a single suit was permissible and in the interest of justice.

For founders and brand owners, this case delivers a clear and urgent message: phonetic and visual similarity between marks is enough to trigger immediate legal consequences, even before a full trial on the merits. If you are building a brand, do not assume that minor tweaks to a competitor's name — such as adding or swapping a letter or two — will insulate you from infringement claims. Equally important, when filing a suit, combining related causes of action like infringement and passing off is not just acceptable; it is often the most efficient and just approach. Protect your brand early, audit the market for confusingly similar names before launch, and remember that in trademark law, perception is everything.